Get startedLog in
    Picture of Tessera Defense and Homeland Security logo

    HLSQ — Tessera Defense and Homeland Security News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapSucker Stock
    All News

    Brief: Biomx Announces Dosing Of The First Two Patients In Phase 1B/2A Study Of Bx004 For Treatment Of Chronic Respiratory Infections In Patients With Cystic Fibrosis

    Picture of Tessera Defense and Homeland Security logoTessera Defense and Homeland Security
    27/06/2022 11:32
    June 27 (Reuters) - Biomx Inc  PHGE.A :
    * BIOMX ANNOUNCES DOSING OF THE FIRST TWO PATIENTS IN PHASE
1B/2A
STUDY OF BX004 FOR TREATMENT OF CHRONIC RESPIRATORY INFECTIONS
IN PATIENTS WITH CYSTIC FIBROSIS
    * BIOMX INC - DATA READOUT FROM PART I OF STUDY EXPECTED IN
3Q
2022

Source text for Eikon:  ID:nBw3DmjZwa 
Further company coverage:  PHGE.A 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Tessera Defense and Homeland Security

    See all news